DNA佐剂阿米洛利联合长免疫间隔可增强HIV-1 gp41与gp140免疫原的抗体应答
该研究以Balb/c小鼠为对象,比较不同免疫间隔及DNA佐剂(吡喹酮、西咪替丁、阿米洛利)对表达三聚体gp41质粒初免、单体gp41或三聚体gp140蛋白及Q577A突变体加强的抗体应答影响。结果显示三种佐剂单独不足以在gp41 DNA免疫后诱导显著特异性抗体,但阿米洛利在蛋白加强后显著促进体液免疫;长免疫间隔可更早诱导更高特异性结合抗体并在末次加强后27周维持高水平。
要点
- 阿米洛利作为DNA佐剂可显著促进蛋白加强后的体液免疫应答。
- 长免疫间隔使特异性结合抗体出现更早、水平更高并维持至末次加强后27周。
- DNA佐剂加强两次配合更长间隔的抗体滴度高于短间隔加强三次。
核心结论
- DNA佐剂阿米洛利与长免疫间隔可增强针对HIV-1 gp41和gp140免疫原的抗体应答,为HIV免疫方案设计提供新思路。
研究设计与样本
- 以Balb/c小鼠为对象,用表达三聚体gp41的质粒初免,分别以单体gp41、三聚体gp140蛋白及Q577A突变体加强。
- 评估不同免疫间隔及吡喹酮、西咪替丁、阿米洛利三种DNA佐剂对erti抗体应答的影响。
主要发现
- 三种佐剂单独不足以在gp41 DNA免疫后诱导显著特异性抗体。
- 阿米洛利在蛋白加强后显著促进体液免疫应答。
- 长免疫间隔使特异性结合抗体出现更早、水平更高,并在末次蛋白加强后27周维持高水平。
- DNA佐剂配合两次蛋白加强及更长间隔的抗体滴度高于短间隔三次蛋白加强。
- Q577A突变体有利于三聚体gp140加强诱导结合抗体但不利于中和抗体,在单体gp41中趋势相反。
临床怎么用
- 在HIV疫苗设计中可考虑将阿米洛利作为DNA佐剂与蛋白加强联合使用。
- 采用较长免疫间隔可能有助于提高并维持特异性抗体水平。
局限性
- 研究为Balb/c小鼠模型,结果外推到人体需进一步验证。
- 未报告具体抗体滴度数值及统计显著性指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies have revealed that the interface of gp120 and gp41 and some parts of gp41 are also critical epitopes for elicitation of broadly neutralizing antibodies. Therefore, potential trimeric gp41 or gp140 immunogen candidates are needed. Previously, we developed a trimer motif MTQ and demonstrated that it could help formation of trimeric gp120 and gp140 proteins. In the present study, we immunized Balb/c mice using trimeric gp41-expressing plasmid for prime and monomeric gp41 or trimeric gp140 protein as well as a mutant (Q577A) for boost. The antibody responses in the context of regimens with various immunization intervals and DNA adjuvants including praziquantel (PZQ), cimetidine (CIM), and amiloride (AML) were evaluated. We found that these three adjuvants were not enough to elicit remarkable specific Abs after gp41 DNA immunization, while AML could significantly promote humoral immune responses after protein boosts. Long immunization interval could induce the specific binding Abs earlier and higher and maintain a high level of Abs in the following 27 weeks after final protein boost. Moreover, two times of protein boosts with DNA adjuvant and a longer time interval achieved a higher titer of specific Abs than three times of protein boosts with a shorter time interval. Q577A mutant was benefit for trimeric gp140 boost in the production of binding Abs but harmful to inducing neutralizing Abs, while this mutant in monomeric gp41 presented the opposite trend which may be associated with the immunogen structures. This study highlights the significance of DNA adjuvant Amiloride and long immunization interval in promoting antibody responses and provides new insights into effective HIV immunization regimen design in the future.
引用
- Yao L, Wang JY, Bao LN, et al. DNA adjuvant Amiloride conjunct long immunization interval promote higher antibody responses to HIV-1 gp41 and gp140 immunogens. Vaccine. 2020. PMID: 33041100. doi:10.1016/j.vaccine.2020.09.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。